CSM Advisors LLC Grows Holdings in AdaptHealth Corp. $AHCO

CSM Advisors LLC raised its holdings in shares of AdaptHealth Corp. (NASDAQ:AHCO) by 13.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 742,335 shares of the company’s stock after purchasing an additional 90,258 shares during the quarter. CSM Advisors LLC’s holdings in AdaptHealth were worth $6,645,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of AdaptHealth by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 60,495 shares of the company’s stock worth $656,000 after purchasing an additional 2,564 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in AdaptHealth by 32.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 571,232 shares of the company’s stock valued at $6,192,000 after buying an additional 139,828 shares in the last quarter. Woodline Partners LP bought a new stake in AdaptHealth during the 1st quarter valued at about $2,851,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in AdaptHealth by 18.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 233,780 shares of the company’s stock valued at $2,534,000 after buying an additional 35,879 shares during the period. Finally, Envestnet Asset Management Inc. boosted its position in AdaptHealth by 115.3% in the 2nd quarter. Envestnet Asset Management Inc. now owns 152,679 shares of the company’s stock valued at $1,440,000 after buying an additional 81,760 shares during the period. 82.67% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at AdaptHealth

In related news, major shareholder Richard M. Cashin, Jr. bought 689,336 shares of the company’s stock in a transaction on Thursday, March 12th. The shares were acquired at an average price of $9.73 per share, with a total value of $6,707,239.28. Following the transaction, the insider owned 15,864,871 shares of the company’s stock, valued at $154,365,194.83. The trade was a 4.54% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders acquired 2,046,691 shares of company stock worth $19,914,303. 1.55% of the stock is currently owned by company insiders.

Key AdaptHealth News

Here are the key news stories impacting AdaptHealth this week:

• Positive Sentiment: Major shareholder Richard M. Cashin Jr. executed multiple buys over March 10–12 totaling roughly 2.05 million shares (~$19.9M) at about $9.73/share, lifting his stake to ~15.86M shares — a strong insider vote of confidence that likely supported the rally. Investing.com article
• Positive Sentiment: Other filings and coverage show the same insider purchases (disclosed to the SEC) and note a multi-day, material increase in Cashin’s position — reinforcing the market interpretation of the buy as strategic accumulation rather than one-off trading. InsiderTrades article
• Positive Sentiment: Institutional activity shows selective buying (e.g., Goldman Sachs, UBS, new position from Woodline), which can add buying pressure and liquidity support. MarketBeat institutional note
• Neutral Sentiment: Analyst coverage is mixed — several “outperform”/buy ratings and raises to price targets offset by some downgrades and cuts; consensus is a moderate-buy with an average target ~ $13.25, so analyst views provide both support and caution. MarketBeat analyst summary
• Neutral Sentiment: Valuation write-ups are assessing the stock after recent weakness — useful for longer-term context but not an immediate catalyst. Yahoo Finance article
• Neutral Sentiment: Reported short-interest data in recent feeds appears inconsistent (shows 0 shares/NaN increases), so don’t read too much into those numbers until corrected filings are available.
• Negative Sentiment: Recent quarterly results (Feb. 24) included a large EPS miss (reported -$0.76 vs. consensus $0.34) and slight revenue decline year-over-year — fundamental weakness that has pressured valuation and explains earlier share-price weakness. SEC / MarketBeat filing

Wall Street Analyst Weigh In

AHCO has been the topic of a number of research reports. Leerink Partners reduced their target price on shares of AdaptHealth from $13.00 to $12.00 and set an “outperform” rating on the stock in a research report on Thursday, February 26th. Weiss Ratings lowered AdaptHealth from a “hold (c-)” rating to a “sell (d)” rating in a report on Wednesday, February 25th. Royal Bank Of Canada reissued an “outperform” rating and issued a $13.00 price objective on shares of AdaptHealth in a research note on Wednesday, February 25th. Wall Street Zen downgraded AdaptHealth from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Finally, Zacks Research raised AdaptHealth from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.25.

AdaptHealth Trading Up 8.7%

NASDAQ:AHCO opened at $10.60 on Friday. The firm has a 50-day simple moving average of $10.10 and a 200-day simple moving average of $9.68. AdaptHealth Corp. has a one year low of $7.11 and a one year high of $11.17. The firm has a market cap of $1.44 billion, a P/E ratio of -19.27, a P/E/G ratio of 1.22 and a beta of 1.76. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.81 and a current ratio of 1.02.

AdaptHealth (NASDAQ:AHCO) last released its quarterly earnings data on Tuesday, February 24th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.34 by ($1.10). The business had revenue of $846.29 million for the quarter, compared to the consensus estimate of $832.51 million. AdaptHealth had a negative net margin of 2.18% and a positive return on equity of 3.42%. AdaptHealth’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.34 earnings per share. Equities analysts anticipate that AdaptHealth Corp. will post 0.88 EPS for the current fiscal year.

About AdaptHealth

AdaptHealth, Inc operates as a leading provider of home medical equipment (HME) and related services in the United States. The company focuses on delivering respiratory care, mobility solutions and bathroom safety products to patients with chronic and acute medical needs. Through its comprehensive service offerings, AdaptHealth aims to enhance quality of life and clinical outcomes for patients who require long-term support outside of a hospital setting.

The company’s respiratory portfolio includes products such as continuous positive airway pressure (CPAP) devices, oxygen concentrators, ventilators, and associated supplies for patients with sleep apnea, COPD and other pulmonary conditions.